A61K 51/1069
The tumor cell being from blood cells
Official title: {the tumor cell being from blood cells, e.g. the cancer being a myeloma}
A61K51/1069 (The tumor cell being from blood cells) appears on 71 US grants and 105 published applications in this corpus.
Search patents in A61K- Granted patents
- 71
- Published applications
- 105
- Assignees
- 46
- Inventors
- 134
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 3 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 2 | 2 |
| 2003 | 2 | 4 |
| 2004 | 0 | 1 |
| 2005 | 1 | 3 |
| 2006 | 0 | 0 |
| 2007 | 2 | 1 |
| 2008 | 0 | 3 |
| 2009 | 0 | 1 |
| 2010 | 4 | 6 |
| 2011 | 1 | 4 |
| 2012 | 3 | 6 |
| 2013 | 3 | 4 |
| 2014 | 2 | 7 |
| 2015 | 3 | 5 |
| 2016 | 7 | 8 |
| 2017 | 3 | 6 |
| 2018 | 4 | 5 |
| 2019 | 5 | 5 |
| 2020 | 1 | 6 |
| 2021 | 1 | 5 |
| 2022 | 4 | 9 |
| 2023 | 3 | 3 |
| 2024 | 3 | 8 |
| 2025 | 2 | 2 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Stabilized radiolabeled anti-CD45 immunoglobulin compositions18 Aug 2026US 12,708,678 B2Actinium Pharmaceuticals, Inc.
- Low dose antibody-based methods for treating hematologic malignancies9 Sep 2025US 12,410,249 B2Actinium Phamaceuticals, Inc.
- LILRB4 antibodies and uses thereof21 Jan 2025US 12,202,895 B2Board of Regents, The University of Texas System
- Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic5 Nov 2024US 12,133,849 B2Actinium Pharmaceuticals, Inc.
- Methods for treatment of patients with myelodysplastic syndromes10 Sep 2024US 12,083,192 B2Actinium Pharmaceuticals, Inc.
- Low dose antibody-based methods for treating hematologic malignancies13 Aug 2026US 2026/0234248 A1Actinium Pharmaceuticals, Inc.
- Novel lilrb4 antibodies and uses thereof7 Aug 2025US 2025/0250336 A1Board of Regents, The University of Texas System
- Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic16 Jan 2025US 2025/0017919 A1Actinium Pharmaceuticals, Inc.
- Methods for treatment of patients with myelodysplastic syndromes12 Dec 2024US 2024/0408250 A1Actinium Pharmaceuticals, Inc.
- Method for treating acute myeloid leukemia using venetoclax in conjunction with lintuzumab-ac22512 Sep 2024US 2024/0299600 A1Actinium Pharmaceuticals, Inc.
Most cited
By later US patents
- Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody199US 6,455,043 B1IDEC Pharmaceuticals Corporation · 2002
- Preparation and use of immunoconjugates182US 5,443,953 AImmunomedics, Inc. · 1995
- Radioimmunotherapy of lymphoma using anti-CD20178US 5,595,721 ACoulter Pharmaceutical, Inc. · 1997
- Preparation and use of immunoconjugates100US 5,635,603 AImmunomedics, Inc. · 1997
- Radioimmunotherapy of lymphoma using anti-CD20 antibodies99US 6,090,365 ACoulter Pharmaceutical, Inc. · 2000